vida: extract claims from 2026-04-22-kff-medicaid-glp1-coverage-13-states

- Source: inbox/queue/2026-04-22-kff-medicaid-glp1-coverage-13-states.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/divergence-glp1-economics-chronic-cost-vs-low-persistence.md

@@ -1,14 +1,13 @@
 ---
 type: divergence
-title: "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?"
 domain: health
 description: "These are opposite cost problems from the same drug class — one assumes lifelong use drives inflation, the other shows 85% discontinuation undermines the chronic model. The answer determines payer strategy, formulary design, and the health domain's cost trajectory claims."
-status: open
-claims:
-  - "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"
-  - "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"
-surfaced_by: leo
 created: 2026-03-19
+status: open
+title: Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
+claims: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+surfaced_by: leo
+related: ["divergence-glp1-economics-chronic-cost-vs-low-persistence", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline"]
 ---
 
 # Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
@@ -53,3 +52,10 @@ Relevant Notes:
 
 Topics:
 - [[_map]]
+
+
+## Extending Evidence
+
+**Source:** KFF Medicaid GLP-1 Coverage Analysis, January 2026
+
+The coverage landscape is bifurcating: some states expanding GLP-1 access while others (California, New Hampshire, Pennsylvania, South Carolina) actively cut it. This creates a policy divergence where budget constraints override clinical benefit logic, with the BALANCE Model (CMS innovation model launching May 2026) attempting federal expansion concurrent with state-level contractions.

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -25,3 +25,10 @@ States with the highest obesity rates (Mississippi, West Virginia, Louisiana at
 **Source:** KFF Medicaid GLP-1 Coverage Analysis, January 2026
 
 As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obesity under fee-for-service Medicaid, despite nearly 40% of adults and 25% of children with Medicaid having obesity. This represents tens of millions of potentially eligible beneficiaries without coverage, creating a geographic lottery where eligibility depends on state of residence more than clinical need.
+
+
+## Extending Evidence
+
+**Source:** KFF Medicaid GLP-1 Coverage Analysis, January 2026
+
+As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obesity under fee-for-service Medicaid, despite nearly 40% of adults and 25% of children with Medicaid having obesity. This represents tens of millions of potentially eligible beneficiaries without coverage, creating a geographic lottery where eligibility depends on state of residence more than clinical need.

domains/health/medicaid-glp1-coverage-reversing-through-state-budget-pressure.md

@@ -24,3 +24,10 @@ As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obes
 **Source:** KFF Medicaid GLP-1 Coverage Analysis, January 2026
 
 Four states actively eliminated GLP-1 obesity coverage in 2025-2026: California, New Hampshire, Pennsylvania, and South Carolina. California's Medi-Cal projected costs rising from $85M in FY2025-26 to $680M by 2028-29, an 8x increase in three years. This represents active reversal of access gains, not just stagnation.
+
+
+## Supporting Evidence
+
+**Source:** KFF Medicaid GLP-1 Coverage Analysis, January 2026
+
+Four states eliminated GLP-1 obesity coverage in 2025-2026 due to budget pressure: California, New Hampshire, Pennsylvania, and South Carolina. California's Medi-Cal projected costs of $85M in FY2025-26 rising to $680M by 2028-29 drove the elimination decision. This represents active reversal of access gains, not just stagnation.